3 Key Takeaways
Plain English Summary- 01Core Finding
To explore these mechanisms, we performed an integrated multi-omics analysis using a mouse model with overexpression of human filamin-A, a cytoskeletal protein genetically implicated in progressive supranuclear palsy.
- 02Study Evidence
Tested in a animal models (11 individuals) at the preclinical stage.
- 03Practical Meaning
In human analyses, post-mortem brain samples from individuals with progressive supranuclear palsy showed reduced dopamine D2 receptor expression compared with neurologically normal controls, together with region-dependent alterations in c-Fos expression and enrichment of activator protein 1-related motifs in regions with reduced chromatin accessibility.
What This Means for You
Multi-layered analyses revealed cortical monoamine depletion together with early striatal dopaminergic sensitization, indicating a close association between immediate early gene dysregulation and dopaminergic circuit imbalance. With ageing, the coupling was lost, coinciding with dopaminergic exhaustion and deficits in locomotor, cognitive and social behaviours. In human analyses, post-mortem brain samples from individuals with progressive supranuclear palsy showed reduced dopamine D2 receptor expression compared with neurologically normal controls, together with region-dependent alterations in c-Fos expression and enrichment of activator protein 1-related motifs in regions with reduced chromatin accessibility. Together, these findings suggest that filamin-A-dependent cytoskeletal stress acts as an upstream molecular context in which immediate early gene-centred transcriptional dysregulation emerges and becomes linked to dopaminergic vulnerability in progressive supranuclear palsy.
The Discovery
Progressive supranuclear palsy is a late-onset neurodegenerative disorder characterized by tau aggregation and prominent dopaminergic dysfunction, yet the upstream molecular processes linking transcriptional abnormalities to dopaminergic failure remain poorly understood. To explore these mechanisms, we performed an integrated multi-omics analysis using a mouse model with overexpression of human filamin-A, a cytoskeletal protein genetically implicated in progressive supranuclear palsy. Analyses were conducted in young adult mice (5-7 months) and aged mice (14-16 months) of both sexes, with transcriptomic, epigenomic, biochemical, metabolomic and behavioural profiling performed across multiple brain regions. In parallel, post-mortem human brain tissue from 11 individuals with progressive supranuclear palsy and five neurologically normal controls was analysed for biochemical validation using samples from the frontal cortex and striatum. Transcriptomic profiling identified immediate early gene-centred transcriptional dysregulation as a prominent and early molecular alteration. This change, accompanied by chromatin accessibility alterations, was associated with the activation of activator protein 1-dependent gene programmes and region-specific changes in dopaminergic protein markers across the cortex, striatum and midbrain. Multi-layered analyses revealed cortical monoamine depletion together with early striatal dopaminergic sensitization, indicating a close association between immediate early gene dysregulation and dopaminergic circuit imbalance.
How It Works, Simply
This neurology research focuses on tau protein · Dopamine · Receptor targeting. Researchers evaluated it using an animal models (11 individuals) at the preclinical stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
To explore these mechanisms, we performed an integrated multi-omics analysis using a mouse model with overexpression of human filamin-A, a cytoskeletal protein genetically implicated in progressive supranuclear palsy.
- 02Study Evidence
Tested in a animal models (11 individuals) at the preclinical stage.
- 03Practical Meaning
In human analyses, post-mortem brain samples from individuals with progressive supranuclear palsy showed reduced dopamine D2 receptor expression compared with neurologically normal controls, together with region-dependent alterations in c-Fos expression and enrichment of activator protein 1-related motifs in regions with reduced chromatin accessibility.
Biological Mechanism & Study Design
Study Design & Cohort
Animal models
Animal models (11 individuals) · Preclinical
Biological Pathway & Modality
Tau protein · Dopamine · Receptor targeting
Intervention: Filamin-A links transcriptional disruption to dopaminergic decline in progressive
Experimental Findings & Endpoints
Progressive supranuclear palsy is a late-onset neurodegenerative disorder characterized by tau aggregation and prominent dopaminergic dysfunction, yet the upstream molecular processes linking transcriptional abnormalities to dopaminergic failure remain poorly understood.
To explore these mechanisms, we performed an integrated multi-omics analysis using a mouse model with overexpression of human filamin-A, a cytoskeletal protein genetically implicated in progressive supranuclear palsy. Analyses were conducted in young adult mice (5-7 months) and aged mice (14-16 months) of both sexes, with transcriptomic, epigenomic, biochemical, metabolomic and behavioural profiling performed across multiple brain regions.
In parallel, post-mortem human brain tissue from 11 individuals with progressive supranuclear palsy and five neurologically normal controls was analysed for biochemical validation using samples from the frontal cortex and striatum. Transcriptomic profiling identified immediate early gene-centred transcriptional dysregulation as a prominent and early molecular alteration.
This change, accompanied by chromatin accessibility alterations, was associated with the activation of activator protein 1-dependent gene programmes and region-specific changes in dopaminergic protein markers across the cortex, striatum and midbrain. Multi-layered analyses revealed cortical monoamine depletion together with early striatal dopaminergic sensitization, indicating a close association between immediate early gene dysregulation and dopaminergic circuit imbalance.
Clinical Translation & Practice Context
Multi-layered analyses revealed cortical monoamine depletion together with early striatal dopaminergic sensitization, indicating a close association between immediate early gene dysregulation and dopaminergic circuit imbalance.
With ageing, the coupling was lost, coinciding with dopaminergic exhaustion and deficits in locomotor, cognitive and social behaviours. In human analyses, post-mortem brain samples from individuals with progressive supranuclear palsy showed reduced dopamine D2 receptor expression compared with neurologically normal controls, together with region-dependent alterations in c-Fos expression and enrichment of activator protein 1-related motifs in regions with reduced chromatin accessibility.
Together, these findings suggest that filamin-A-dependent cytoskeletal stress acts as an upstream molecular context in which immediate early gene-centred transcriptional dysregulation emerges and becomes linked to dopaminergic vulnerability in progressive supranuclear palsy.
The Bottom Line · Clinical Pearl
“Together, these findings suggest that filamin-A-dependent cytoskeletal stress acts as an upstream molecular context in which immediate early gene-centred transcriptional dysregulation emerges and becomes linked to dopaminergic vulnerability in progressive supranuclear palsy.”
Published in Brain: A Journal of Neurology · Current Stage: Preclinical
